TNFRSF8 and B-cell non-Hodgkin lymphoma: For B‐cell NHL, the subset of phase 2 NCT01421667 study showed the efficacy of BV for patients with R/R CD30‐positive B‐cell NHL, mainly DLBCL, with an ORR of 44% and a CR rate of 17%.80